Valuation: Nexalis Therapeutics Limited

Market Cap 2.02M 1.35M 1.23M 1.14M 1.03M 1.93M 126M 13.78M 5.47M 68.2M 5.07M 4.96M 216M P/E 2024
-6.17x
P/E 2025 -3.2x
Enterprise Value 2.33M 1.55M 1.42M 1.31M 1.19M 2.22M 145M 15.85M 6.29M 78.46M 5.83M 5.71M 249M EV / Sales 2024
18.2x
EV / Sales 2025 6.13x
Free-Float
48.36%
Yield 2024 *
-
Yield 2025 -
Current month-11.11%
1 month-11.11%
3 months-27.27%
6 months-63.64%
Current year-66.67%
1 week 0.01
Extreme 0.008
0.01
1 month 0.01
Extreme 0.008
0.01
Current year 0.01
Extreme 0.007
0.03
1 year 0.01
Extreme 0.007
0.04
3 years 0.01
Extreme 0.007
0.05
5 years 0.01
Extreme 0.007
0.13
10 years 0.01
Extreme 0.007
0.44
Manager TitleAgeSince
Chief Executive Officer - 27/09/2022
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - 27/09/2022
Director TitleAgeSince
Director/Board Member - 25/06/2026
Director/Board Member - 12/05/2026
Chairman - 02/10/2026
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-72.41%-79.49% 1.36M
+0.19%-2.90%+56.40%+69.15% 65.45B
-0.14%-1.96%+8.83%+89.74% 58.93B
+0.06%+0.51%+26.04%+87.89% 55.21B
-0.97%-4.83%+9.83%+113.88% 46.1B
-2.83%-8.73%+15.31%+22.34% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
-0.24%-11.77%+125.89%+647.44% 34.57B
+0.03%-1.80%+82.52%+57.74% 32.46B
+20.58%+19.64%-28.35%+482.03% 26.28B
Average +0.20%-2.64%+24.69%+153.71% 40B
Weighted average by Cap. +0.06%-2.69%+34.88%+149.70%

Financials

2024 2025
Net sales 402K 268K 244K 226K 205K 384K 25.05M 2.73M 1.08M 13.54M 1.01M 985K 42.88M 986K 659K 600K 555K 502K 942K 61.5M 6.71M 2.66M 33.24M 2.47M 2.42M 105M
Net income -1.21M -807K -736K -681K -616K -1.16M -75.4M -8.23M -3.27M -40.75M -3.03M -2.97M -129M -1.62M -1.08M -985K -911K -824K -1.55M -101M -11.02M -4.37M -54.54M -4.05M -3.97M -173M
Net Debt -161K -107K -97.84K -90.57K -81.92K -154K -10.03M -1.09M -434K -5.42M -403K -394K -17.17M 304K 203K 185K 171K 155K 291K 18.98M 2.07M 822K 10.26M 762K 746K 32.49M
Projected Income Statement - Annual - Nexalis Therapeutics Limited
Logo Nexalis Therapeutics Limited
Nexalis Therapeutics Ltd, formerly InhaleRx Limited, is an Australia-based clinical stage drug development company. The Company is focused on developing onset, inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The Company is focused on the development of IRX-211 to treat Breakthrough Cancer Pain (BTcP), and IRX-616a to treat panic disorders (PD) and SRX-25 for the treatment of Treatment-Resistant Depression (TRD). The Company operates through segment development of medicinal drug-device products to address unmet medical needs. Its IRX-211 focuses on the management of BTcP with non-opioid, onset inhaled therapy. The Phase I clinical trials for IRX-211 have been completed. Its IRX-616a is an approved inhaled medication for panic disorder, offering a novel treatment avenue.
Employees
-
Date Price Change Volume
13/11/26 A$0.008000 0.00% 1,080,550